Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Obesity Treatments

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

The filing positions a potential 2026 FDA review for what could be the first fixed‑dose GLP‑1 and amylin combination therapy.

Lilly’s Triple‑Agonist Retatrutide Delivers Up to 28.7% Weight Loss in Phase 3, Easing Knee Pain

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

Novo Nordisk Raises Metsera Bid to $10 Billion, Outpacing Pfizer’s $8.1 Billion Counter

Lilly’s Orforglipron Pill Hits Phase 3 Goals and Outperforms Oral Semaglutide in Diabetes Study

Lilly’s Orforglipron Pill Hits Phase 3 Goals, Clearing Path to Global Filings

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial